The spending focused on rural upliftment and patient awareness programmes, reflecting Lupin’s long-standing commitment to community welfare and equitable healthcare access.
MUMBAI (India CSR): Leading Indian pharmaceutical company Lupin Limited has reported a Corporate Social Responsibility (CSR) expenditure of Rs. 24.99 crore for the financial year ended March 31, 2025. Against a mandated CSR requirement of Rs. 33.49 crore, the company recorded a shortfall of Rs. 8.5 crore, which has been duly carried forward and deposited in a specified bank account within the prescribed timelines, in line with the Companies Act 2013.
CSR Expenditure Overview
- Amount required to be spent (FY 2024-25): ₹33.49 crore
- Amount approved by the Board: ₹33.49 crore
- Actual amount spent during the year: ₹24.99 crore
- Shortfall at year end: ₹8.5 crore
- Previous years’ shortfall: Nil
- Nature of CSR activities: Rural development, patient awareness, and other activities under Schedule VII of the Companies Act 2013
- Related-party transactions in CSR activities: ₹17.34 crore (previous year ₹22.80 crore)
CSR Spending Focus Areas
Lupin’s CSR efforts during FY 2024-25 were focused on rural support programmes, public health awareness, and initiatives that align with the broader national development agenda outlined in Schedule VII of the Companies Act.
The company confirmed that no funds were used for the construction or acquisition of assets during the year, and no outstanding payables remain for CSR obligations.
The shortfall amount of Rs. 8.5 crore has been transferred to a specified bank account, ensuring compliance with Section 135(6) of the Companies Act and the CSR Rules, 2021, which require unspent CSR amounts for ongoing projects to be deposited in a dedicated account before the end of the financial year.
Compliance and Transparency
The company stated that it has adhered to the Guidance Note on Accounting for CSR Expenditure issued by the Institute of Chartered Accountants of India (ICAI). The CSR figures have been disclosed separately under Note 33 in the Integrated Annual Report 2024-25.
There was no creation of capital assets related to CSR, reaffirming Lupin’s focus on community-driven programme implementation rather than infrastructure investment.
Expert Perspective
Corporate governance analysts note that the Rs. 8.5 crore shortfall — nearly 25 percent of the mandated CSR allocation — underscores the challenges companies face in executing large-scale CSR projects within a single fiscal year. However, Lupin’s timely deposit of the unspent amount demonstrates regulatory discipline and commitment to carry forward CSR obligations transparently.
CSR experts suggest that the upcoming fiscal year will be crucial for Lupin as it must ensure the deployment of the carried-forward ₹8.5 crore towards ongoing projects and report measurable social impact outcomes in rural and healthcare sectors.
Background
In the previous financial year (FY 2023-24), Lupin had spent Rs. 25.26 crore on CSR activities — slightly higher than this year’s spend. The reduction reflects the company’s evolving strategy to recalibrate CSR focus areas amid changing healthcare priorities and rural outreach challenges.
The company’s CSR model continues to align with its flagship Lupin Human Welfare & Research Foundation (LHWRF), which has worked for over three decades in promoting integrated rural development, healthcare access, education, and women’s empowerment across India.
Terms & Conditions: India CSR does not permit other Websites/agencies to copy or reproduce, or reprint the above article/feature in any form or means.
